Zoe Harcombe on kysellyt Sir Rory "Roisto" Collinsilta:
Lainaa:
Dear Professor Collins
Please can you point me to where in your recent Lancet paper I can find the source for/data behind these two statements in the abstract?
1) “For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per month) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% absolute benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolute benefit) who are at increased risk but have not yet had a vascular event (primary prevention).”
And
2) “Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50–100 new cases of diabetes, and 5–10 haemorrhagic strokes… Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50–100 patients (ie, 0·5–1·0% absolute harm) per 10 000 treated for 5 years. ”
Many thanks
Kind regards – Zoe
ja
Lainaa:
Dear Professor Collins
I appreciate that you may have had many emails since The Lancet article, but please do you have a time scale for replying to my email below?
Many thanks
Kind regards – Zoe
Vastausta ei ole kuulunut. Collinsin koplan statiineja puolustelevat väitteet Lancetissa ovat pelkkää LÄPPÄÄ.